Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 14/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8420834 | 1.00 | ESR1 (0.46) | ESR1KCNH2ACACBGAANPC1 | |
| SCHEMBL6678014 | 1.00 | ESR1 (0.46) | ESR1KCNH2ACACBGAANPC1 | |
| SCHEMBL9185371 | 0.86 | GAA (0.41) | ACACBGAANPC1RAB9A | |
| SCHEMBL6539913 | 0.84 | ESR1 (0.46) | ESR1KCNH2ACACBGAANPC1 | |
| SCHEMBL6541437 | 0.84 | ESR1 (0.46) | ESR1KCNH2ACACBGAANPC1 | |
| SCHEMBL12204087 | 0.82 | ACACB (0.57) | ESR1KCNH2ACACBNPC1RAB9A | |
| SCHEMBL6677082 | 0.82 | ACACB (0.50) | ESR1KCNH2ACACBGAANPC1 | |
| SCHEMBL8986819 | 0.81 | ESR1 (0.54) | ESR1KCNH2ACACBNPC1RAB9A | |
| SCHEMBL8986825 | 0.81 | ESR1 (0.54) | ESR1KCNH2ACACBNPC1RAB9A | |
| SCHEMBL11959175 | 0.81 | ACACB (0.56) | ESR1KCNH2ACACBGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |
| EP-1389185-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094770-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | ESR1 2525/4885KCNH2 211/4885ACACB 3020/4885 |
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | ESR1 3850/4885KCNH2 184/4885ACACB 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.